Compare Stocks: CDTX, ROIV, INCY, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$91.19 -1.1%	$91.41	$79.52 ▼ $124.00	$23.31B	1.27	893,193 shs	1.35 million shs
CDTX Cidara Therapeutics	$221.38 +0.0%	$220.96	$18.51 ▼ $221.42	$6.96B	1.52	928,762 shs	2.69 million shs
INCY Incyte	$118.38 -1.2%	$111.31	$76.79 ▼ $132.60	$24.28B	0.76	1.93 million shs	2.39 million shs
ROIV Roivant Sciences	$35.12 +1.5%	$33.00	$10.90 ▼ $37.00	$24.89B	1.12	4.72 million shs	8.25 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+0.91%	-0.83%	-1.86%	-0.90%	-17.01%
CDTX Cidara Therapeutics	0.00%	0.00%	0.00%	0.00%	+258.39%
INCY Incyte	-0.66%	-5.74%	+3.62%	+22.53%	+54.14%
ROIV Roivant Sciences	+0.03%	+5.26%	-2.23%	+22.35%	+197.51%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$91.19 -1.1%	$91.41	$79.52 ▼ $124.00	$23.31B	1.27	893,193 shs	1.35 million shs
CDTX Cidara Therapeutics	$221.38 +0.0%	$220.96	$18.51 ▼ $221.42	$6.96B	1.52	928,762 shs	2.69 million shs
INCY Incyte	$118.38 -1.2%	$111.31	$76.79 ▼ $132.60	$24.28B	0.76	1.93 million shs	2.39 million shs
ROIV Roivant Sciences	$35.12 +1.5%	$33.00	$10.90 ▼ $37.00	$24.89B	1.12	4.72 million shs	8.25 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+0.91%	-0.83%	-1.86%	-0.90%	-17.01%
CDTX Cidara Therapeutics	0.00%	0.00%	0.00%	0.00%	+258.39%
INCY Incyte	-0.66%	-5.74%	+3.62%	+22.53%	+54.14%
ROIV Roivant Sciences	+0.03%	+5.26%	-2.23%	+22.35%	+197.51%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$127.81	40.16% Upside
CDTX Cidara Therapeutics	2.30	Hold	$169.88	-23.27% Downside
INCY Incyte	2.43	Hold	$120.40	1.71% Upside
ROIV Roivant Sciences	2.83	Moderate Buy	$33.59	-4.35% Downside

Current Analyst Ratings Breakdown

Latest CDTX, ROIV, INCY, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2026	ROIV Roivant Sciences	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$142.00
8/5/2026	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$130.00 ➝ $125.00
8/4/2026	INCY Incyte	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$121.00 ➝ $137.00
8/3/2026	INCY Incyte	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	INCY Incyte	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$131.00 ➝ $155.00
7/31/2026	ROIV Roivant Sciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	INCY Incyte	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
7/29/2026	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$99.00 ➝ $109.00
7/29/2026	INCY Incyte	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$136.00 ➝ $150.00
7/29/2026	INCY Incyte	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$119.00

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.10	$1.32 per share	69.04	$81.64 per share	1.12
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	$14.92 per share	N/A
INCY Incyte	$5.14B	4.67	$6.11 per share	19.38	$31.30 per share	3.78
ROIV Roivant Sciences	$8.26M	3,058.20	N/A	N/A	$7.35 per share	4.78

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$11.78	N/A	N/A	N/A	N/A	-45.52%	-38.31%	N/A
INCY Incyte	$1.29B	$7.85	15.08	14.93	3.76	27.71%	29.93%	22.88%	N/A
ROIV Roivant Sciences	-$299.77M	-$0.60	N/A	N/A	N/A	-3,629.19%	-20.54%	-19.43%	8/6/2026 (Estimated)

Latest CDTX, ROIV, INCY, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	8.74
CDTX Cidara Therapeutics	N/A	4.62	4.62
INCY Incyte	N/A	4.59	4.51
ROIV Roivant Sciences	N/A	18.37	18.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
CDTX Cidara Therapeutics	35.82%
INCY Incyte	96.97%
ROIV Roivant Sciences	64.76%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
CDTX Cidara Therapeutics	3.89%
INCY Incyte	16.20%
ROIV Roivant Sciences	8.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
CDTX Cidara Therapeutics	90	31.44 million	30.22 million	No Data
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
ROIV Roivant Sciences	860	719.27 million	655.97 million	Optionable

CDTX, ROIV, INCY, and BNTX Headlines

Recent News About These Companies

Roivant outlines brepocitinib DM launch by end of September and targets cutaneous sarcoidosis Phase III data in 2028

3 hours ago | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Q1 2026 Earnings Call Transcript

August 6 at 5:00 PM | seekingalpha.com

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

August 6 at 10:51 AM | zacks.com

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

August 6 at 9:01 AM | markets.businessinsider.com

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

August 6 at 7:00 AM | globenewswire.com

Ausblick: Roivant Sciences stellt Ergebnisse des abgelaufenen Quartals vor

August 5 at 2:54 AM | finanzen.netF

Edgestream Partners L.P. Takes Position in Roivant Sciences Ltd. $ROIV

August 4 at 3:51 AM | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Purchased by California State Teachers Retirement System

August 4 at 3:36 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Grows Position in Roivant Sciences Ltd. $ROIV

August 4 at 3:12 AM | marketbeat.com

Hsbc Holdings PLC Sells 31,577 Shares of Roivant Sciences Ltd. $ROIV

August 3 at 4:31 AM | marketbeat.com

Amundi Has $41.02 Million Stake in Roivant Sciences Ltd. $ROIV

August 3 at 3:04 AM | marketbeat.com

Seven Fleet Capital Management LP Purchases New Shares in Roivant Sciences Ltd. $ROIV

August 2, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Position Raised by Perceptive Advisors LLC

August 2, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Has $19.37 Million Stake in Roivant Sciences Ltd. $ROIV

August 2, 2026 | marketbeat.com

Janus Henderson Group PLC Purchases 177,339 Shares of Roivant Sciences Ltd. $ROIV

August 1, 2026 | marketbeat.com

Empowered Funds LLC Grows Stake in Roivant Sciences Ltd. $ROIV

August 1, 2026 | marketbeat.com

First Trust Advisors LP Purchases 195,101 Shares of Roivant Sciences Ltd. $ROIV

July 31, 2026 | marketbeat.com

Roivant Sciences (ROIV) Expected to Post Quarterly Earnings on Thursday

July 30, 2026 | marketbeat.com

Roivant Sciences Ltd. $ROIV Shares Sold by Stempoint Capital LP

July 30, 2026 | marketbeat.com

Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares

July 30, 2026 | insidertrades.com

Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, ROIV, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

$91.19 -0.99 (-1.07%)

Closing price 04:00 PM Eastern

Extended Trading

$90.64 -0.55 (-0.60%)

As of 06:21 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Cidara Therapeutics NASDAQ:CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Incyte NASDAQ:INCY

$118.38 -1.42 (-1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$118.52 +0.14 (+0.12%)

As of 06:39 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Roivant Sciences NASDAQ:ROIV

$35.12 +0.52 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$36.17 +1.05 (+3.00%)

As of 06:50 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDTX, ROIV, INCY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDTX, ROIV, INCY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDTX, ROIV, INCY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, ROIV, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Cidara Therapeutics NASDAQ:CDTX

Incyte NASDAQ:INCY

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CDTX, ROIV, INCY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CDTX, ROIV, INCY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CDTX, ROIV, INCY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDTX, ROIV, INCY, and BNTX Company Descriptions

BioNTech NASDAQ:BNTX

Cidara Therapeutics NASDAQ:CDTX

Incyte NASDAQ:INCY

Roivant Sciences NASDAQ:ROIV

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools